{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:30:21Z","timestamp":1792121421872,"version":"4.4.0"},"reference-count":148,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T00:00:00Z","timestamp":1643068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>In 2014 and 2021, two nucleic-acid vaccine candidates named MAV E2 and VGX-3100 completed phase III clinical trials in Mexico and U.S., respectively, for patients with human papillomavirus (HPV)-related, high-grade squamous intraepithelial lesions (HSIL). These well-tolerated but still unlicensed vaccines encode distinct HPV antigens (E2 versus E6+E7) to elicit cell-mediated immune responses; their clinical efficacy, as measured by HSIL regression or cure, was modest when compared with placebo or surgery (conization), but both proved highly effective in clearing HPV infection, which should help further optimize strategies for enhancing vaccine immunogenicity, toward an ultimate goal of preventing malignancies in millions of patients who are living with persistent, oncogenic HPV infection but are not expected to benefit from current, prophylactic vaccines. The major roadblocks to a highly efficacious and practical product remain challenging and can be classified into five categories: (i) getting the vaccines into the right cells for efficient expression and presentation of HPV antigens (fusion proteins or epitopes); (ii) having adequate coverage of oncogenic HPV types, beyond the current focus on HPV-16 and -18; (iii) directing immune protection to various epithelial niches, especially anogenital mucosa and upper aerodigestive tract where HPV-transformed cells wreak havoc; (iv) establishing the time window and vaccination regimen, including dosage, interval and even combination therapy, for achieving maximum efficacy; and (v) validating therapeutic efficacy in patients with poor prognosis because of advanced, recurrent or non-resectable malignancies. Overall, the room for improvements is still large enough that continuing efforts for research and development will very likely extend into the next decade.<\/jats:p>","DOI":"10.3390\/v14020239","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T20:42:26Z","timestamp":1643143346000},"page":"239","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Therapeutic DNA Vaccines against HPV-Related Malignancies: Promising Leads from Clinical Trials"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0137-7486","authenticated-orcid":false,"given":"Jianming","family":"Tang","sequence":"first","affiliation":[{"name":"Aeonvital Biomedical Research Institute, Beijing 102208, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Peking University People\u2019s Hospital, Beijing 100033, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Peking University People\u2019s Hospital, Beijing 100033, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danhua","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Peking University People\u2019s Hospital, Beijing 100033, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[{"name":"Aeonvital Biomedical Research Institute, Beijing 102208, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Aeonvital Biomedical Research Institute, Beijing 102208, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-6691","authenticated-orcid":false,"given":"Lihui","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Peking University People\u2019s Hospital, Beijing 100033, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1158\/1055-9965.EPI-04-0551","article-title":"Human papillomavirus types in head and neck squamous cell carcinomas worldwide: A systematic review","volume":"14","author":"Kreimer","year":"2005","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/488S2a","article-title":"HPV: The global burden","volume":"488","author":"Crow","year":"2012","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1470-2045(12)70137-7","article-title":"Global burden of cancers attributable to infections in 2008: A review and synthetic analysis","volume":"13","author":"Ferlay","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"F55","DOI":"10.1016\/j.vaccine.2012.06.083","article-title":"The biology and life-cycle of human papillomaviruses","volume":"30","author":"Doorbar","year":"2012","journal-title":"Vaccine"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"F12","DOI":"10.1016\/j.vaccine.2012.07.055","article-title":"Global burden of human papillomavirus and related diseases","volume":"30","author":"Forman","year":"2012","journal-title":"Vaccine"},{"key":"ref_6","first-page":"637","article-title":"Human papilloma virus: Apprehending the link with carcinogenesis and unveiling new research avenues (Review)","volume":"52","author":"Boda","year":"2018","journal-title":"Int. J. Oncol."},{"key":"ref_7","first-page":"107","article-title":"Designing of CD8+ and CD8+-overlapped CD4+ epitope vaccine by targeting late and early proteins of human papillomavirus","volume":"12","author":"Kaliamurthi","year":"2018","journal-title":"Biologics"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/eos.12538","article-title":"Oral manifestations of human papillomavirus infections","volume":"126","author":"Syrjanen","year":"2018","journal-title":"Eur. J. Oral Sci."},{"key":"ref_9","unstructured":"(2021, October 28). Centers for Disease Congtrol and Prevention (CDC) Cancers Caused by HPV, Available online: https:\/\/www.cdc.gov\/hpv\/parents\/cancer.html."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2147\/ITT.S273327","article-title":"Therapeutic Vaccines for HPV-Associated Malignancies","volume":"9","author":"Roller","year":"2020","journal-title":"Immunotargets Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1056\/NEJMp078053","article-title":"Introducing HPV vaccine in developing countries\u2014Key challenges and issues","volume":"356","author":"Agosti","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_12","first-page":"327","article-title":"HPV & HPV vaccination: Issues in developing countries","volume":"130","author":"Bharadwaj","year":"2009","journal-title":"Indian J. Med. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(12)60919-2","article-title":"Global burden of cancer in 2008: A systematic analysis of disability-adjusted life-years in 12 world regions","volume":"380","author":"Soerjomataram","year":"2012","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/sj.clpt.6100055","article-title":"GARDASIL: Prophylactic human papillomavirus vaccine development\u2014From bench top to bed-side","volume":"81","author":"Shi","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"407","DOI":"10.4161\/hv.6.5.11023","article-title":"Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine","volume":"6","author":"Deschuyteneer","year":"2010","journal-title":"Hum. Vaccines"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"705","DOI":"10.4161\/hv.5.10.9518","article-title":"Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18\u201345 years","volume":"5","author":"Einstein","year":"2009","journal-title":"Hum. Vaccines"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bpobgyn.2020.02.009","article-title":"HPV vaccination and cancer prevention","volume":"65","author":"Athanasiou","year":"2020","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"212.e1","DOI":"10.1016\/j.ajog.2016.02.021","article-title":"Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment","volume":"215","author":"Hildesheim","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_19","first-page":"197","article-title":"Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products","volume":"12","author":"Munger","year":"1992","journal-title":"Cancer Surv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4143\/crt.2005.37.6.319","article-title":"The role of HPV E6 and E7 oncoproteins in HPV-associated cervical carcinogenesis","volume":"37","author":"Yim","year":"2005","journal-title":"Cancer Res. Treat."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11262-009-0412-8","article-title":"The biological properties of E6 and E7 oncoproteins from human papillomaviruses","volume":"40","author":"Ghittoni","year":"2010","journal-title":"Virus Genes"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3109\/07853890.2016.1145796","article-title":"Cervical cancer: A comprehensive approach towards extermination","volume":"48","author":"Bava","year":"2016","journal-title":"Ann. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s12026-009-8141-6","article-title":"Therapeutic HPV DNA vaccines","volume":"47","author":"Lin","year":"2010","journal-title":"Immunol. Res."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Boilesen, D.R., Nielsen, K.N., and Holst, P.J. (2021). Novel Antigenic Targets of HPV Therapeutic Vaccines. Vaccines, 9.","DOI":"10.3390\/vaccines9111262"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4161\/hv.4.6.6200","article-title":"Molecular and cellular mechanisms of DNA vaccines","volume":"4","author":"Coban","year":"2008","journal-title":"Hum. Vaccines"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1476-8518-7-3","article-title":"Prospects for control of emerging infectious diseases with plasmid DNA vaccines","volume":"7","author":"Moss","year":"2009","journal-title":"J. Immune Based Ther. Vaccines"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.drudis.2019.12.003","article-title":"Comparison of DNA and Mrna vaccines against cancer","volume":"25","author":"Jahanafrooz","year":"2020","journal-title":"Drug Discov. Today"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"633776","DOI":"10.3389\/fcell.2021.633776","article-title":"A Guide to Nucleic Acid Vaccines in the Prevention and Treatment of Infectious Diseases and Cancers: From Basic Principles to Current Applications","volume":"9","author":"Qin","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3233\/CBM-2005-12-306","article-title":"Early non-invasive diagnosis of cervical cancer: Beyond Pap smears and human papilloma virus (HPV) testing","volume":"1","author":"Mathur","year":"2005","journal-title":"Cancer Biomark."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-19-0211","article-title":"Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer","volume":"25","author":"Chera","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12951-020-0577-9","article-title":"Early-stage cervical cancer diagnosis based on an ultra-sensitive electrochemical DNA nanobiosensor for HPV-18 detection in real samples","volume":"18","author":"Mahmoodi","year":"2020","journal-title":"J. Nanobiotechnol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e20200389","DOI":"10.1084\/jem.20200389","article-title":"Profiling HPV-16-specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients","volume":"217","author":"Bhatt","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41586-021-03862-z","article-title":"Functional HPV-specific PD-1+ stem-like CD8 T cells in head and neck cancer","volume":"597","author":"Eberhardt","year":"2021","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"8468","DOI":"10.1128\/JVI.78.16.8468-8476.2004","article-title":"Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6","volume":"78","author":"Peng","year":"2004","journal-title":"J. Virol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/eji.1830230929","article-title":"Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells","volume":"23","author":"Feltkamp","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/j.vaccine.2017.03.025","article-title":"Identification and characterization of enhancer agonist human cytotoxic T-cell epitopes of the human papillomavirus type 16 (HPV16) E6\/E7","volume":"35","author":"Tsang","year":"2017","journal-title":"Vaccine"},{"key":"ref_38","first-page":"1003","article-title":"Patterns of CD8 T-cell epitopes within the human papillomavirus type 16 (HPV 16) E6 protein among young women whose HPV 16 infection has become undetectable","volume":"12","author":"Nakagawa","year":"2005","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1128\/JVI.01768-06","article-title":"HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein","volume":"81","author":"Nakagawa","year":"2007","journal-title":"J. Virol."},{"key":"ref_40","first-page":"889","article-title":"Different methods of identifying new antigenic epitopes of human papillomavirus type 16 E6 and E7 proteins","volume":"11","author":"Nakagawa","year":"2004","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5934","DOI":"10.4049\/jimmunol.154.11.5934","article-title":"Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides","volume":"154","author":"Ressing","year":"1995","journal-title":"J. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1002\/cncr.26468","article-title":"Identification of novel immunogenic human leukocyte antigen-A 2402-binding epitopes of human papillomavirus type 16 E7 for immunotherapy against human cervical cancer","volume":"118","author":"Jang","year":"2012","journal-title":"Cancer"},{"key":"ref_43","first-page":"788s","article-title":"Human T-cell responses to HLA-A-restricted high binding affinity peptides of human papillomavirus type 18 proteins E6 and E7","volume":"7","author":"Rudolf","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.4161\/cbt.8.21.9732","article-title":"Identification of HLA-A11-restricted CTL epitopes derived from HPV type 18 using DNA immunization","volume":"8","author":"Chen","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12967-014-0229-7","article-title":"Identification of novel epitopes from human papillomavirus type 18 E7 that can sensitize PBMCs of multiple HLA class I against human cervical cancer","volume":"12","author":"Kim","year":"2014","journal-title":"J. Transl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1006\/gyno.2001.6205","article-title":"Synthetic peptides induce a cytotoxic response against human papillomavirus type-18","volume":"82","author":"Castellanos","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.vaccine.2008.10.062","article-title":"WHO meeting on the standardization of HPV assays and the role of the WHO HPV Laboratory Network in supporting vaccine introduction held on 24\u201325 January 2008, Geneva, Switzerland","volume":"27","author":"Ferguson","year":"2009","journal-title":"Vaccine"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1745a","DOI":"10.1093\/ije\/dyx050","article-title":"Cohort Profile: African Collaborative Center for Microbiome and Genomics Research\u2019s (ACCME\u2019s) Human Papillomavirus (HPV) and Cervical Cancer Study","volume":"46","author":"Adebamowo","year":"2017","journal-title":"Int. J. Epidemiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"106235","DOI":"10.1016\/j.ypmed.2020.106235","article-title":"A quality improvement collaborative to increase human papillomavirus vaccination rates in local health department clinics","volume":"139","author":"Li","year":"2020","journal-title":"Prev. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1177\/0969141320943634","article-title":"The effectiveness of human papillomavirus load, reflected by cycle threshold values, for the triage of HPV-positive self-samples in cervical cancer screening","volume":"28","author":"Song","year":"2021","journal-title":"J. Med. Screen."},{"key":"ref_51","unstructured":"World Health Organization (WHO) (2021, November 17). Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240014107."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-1-4939-2013-6_7","article-title":"Robust HPV-18 production in organotypic cultures of primary human keratinocytes","volume":"1249","author":"Wang","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"ref_53","first-page":"21","article-title":"Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen","volume":"56","author":"Lin","year":"1996","journal-title":"Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.4049\/jimmunol.167.9.5420","article-title":"Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6","volume":"167","author":"Evans","year":"2001","journal-title":"J. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/ijc.31027","article-title":"Immune evasion mechanisms of human papillomavirus: An update","volume":"142","author":"Steinbach","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3389\/fonc.2019.00682","article-title":"Papillomavirus Immune Evasion Strategies Target the Infected Cell and the Local Immune System","volume":"9","author":"Zhou","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2217\/fmb.10.107","article-title":"Human papillomavirus: Gene expression, regulation and prospects for novel diagnostic methods and antiviral therapies","volume":"5","author":"Graham","year":"2010","journal-title":"Future Microbiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.3390\/v7072802","article-title":"Human Papillomaviruses; Epithelial Tropisms, and the Development of Neoplasia","volume":"7","author":"Egawa","year":"2015","journal-title":"Viruses"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1002\/path.4496","article-title":"Pathogenesis of human papillomavirus-associated mucosal disease","volume":"235","author":"Groves","year":"2015","journal-title":"J. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Martinez-Perez, A.G., Perez-Trujillo, J.J., Garza-Morales, R., Ramirez-Avila, N.E., Loera-Arias, M.J., Gomez-Gutierrez, J.G., Saucedo-Cardenas, O., Garcia-Garcia, A., Rodriguez-Rocha, H., and Montes-de-Oca-Luna, R. (2021). An Oncolytic Adenovirus Encoding SA-4-1BBL Adjuvant Fused to HPV-16 E7 Antigen Produces a Specific Antitumor Effect in a Cancer Mouse Model. Vaccines, 9.","DOI":"10.3390\/vaccines9020149"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1007\/s12033-021-00374-z","article-title":"In Silico Design and Immunological Studies of Two Novel Multiepitope DNA-Based Vaccine Candidates Against High-Risk Human Papillomaviruses","volume":"63","author":"Kayyal","year":"2021","journal-title":"Mol. Biotechnol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Panahi, H.A., Bolhassani, A., Javadi, G., and Noormohammadi, Z. (2018). A comprehensive in silico analysis for identification of therapeutic epitopes in HPV16, 18, 31 and 45 oncoproteins. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0205933"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10529-020-02792-6","article-title":"Development of HPV16,18,31,45 E5 and E7 peptides-based vaccines predicted by immunoinformatics tools","volume":"42","author":"Namvar","year":"2020","journal-title":"Biotechnol. Lett."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1128\/JVI.78.3.1333-1343.2004","article-title":"Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL\/6 mice","volume":"78","author":"Chen","year":"2004","journal-title":"J. Virol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4161\/hv.34303","article-title":"Anti-tumor effects of genetic vaccines against HPV major oncogenes","volume":"11","author":"Cordeiro","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12985-019-1168-y","article-title":"Identification of variants and therapeutic epitopes in HPV-33\/HPV-58 E6 and E7 in Southwest China","volume":"16","author":"He","year":"2019","journal-title":"Virol. J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.biologicals.2015.07.002","article-title":"Identification of immunotherapeutic epitope of E5 protein of human papillomavirus-16: An in silico approach","volume":"43","author":"Kumar","year":"2015","journal-title":"Biologicals"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s11596-013-1189-5","article-title":"HPV16 E5 peptide vaccine in treatment of cervical cancer in vitro and in vivo","volume":"33","author":"Liao","year":"2013","journal-title":"J. Huazhong Univ. Sci. Technol. Med. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"9083","DOI":"10.1128\/JVI.74.19.9083-9089.2000","article-title":"Induction of CD8 T cells by vaccination with recombinant adenovirus expressing human papillomavirus type 16 E5 gene reduces tumor growth","volume":"74","author":"Liu","year":"2000","journal-title":"J. Virol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1128\/JVI.02256-06","article-title":"Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients","volume":"81","author":"Liu","year":"2007","journal-title":"J. Virol."},{"key":"ref_71","first-page":"D948","article-title":"IPD-IMGT\/HLA Database","volume":"48","author":"Robinson","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00251-015-0875-9","article-title":"HLA supertype variation across populations: New insights into the role of natural selection in the evolution of HLA-A and HLA-B polymorphisms","volume":"67","author":"Buhler","year":"2015","journal-title":"Immunogenetics"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"595039","DOI":"10.3389\/fimmu.2020.595039","article-title":"Experimental Nanovaccine Offers Protection Against Repeat Exposures to Trypanosoma cruzi Through Activation of Polyfunctional T Cell Response","volume":"11","author":"Chowdhury","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.omtm.2020.04.009","article-title":"Nanoplasmid Vectors Co-expressing Innate Immune Agonists Enhance DNA Vaccines for Venezuelan Equine Encephalitis Virus and Ebola Virus","volume":"17","author":"Suschak","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e03224-20","DOI":"10.1128\/mBio.03224-20","article-title":"Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody","volume":"12","author":"Peng","year":"2021","journal-title":"mBio"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.immuni.2017.10.009","article-title":"CD4+ T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness","volume":"47","author":"Ahrends","year":"2017","journal-title":"Immunity"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Hobernik, D., and Bros, M. (2018). DNA Vaccines-How Far From Clinical Use?. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113605"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1158\/0008-5472.CAN-15-3130","article-title":"CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination","volume":"76","author":"Ahrends","year":"2016","journal-title":"Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1089\/10430340460745757","article-title":"Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus","volume":"15","author":"Gutierrez","year":"2004","journal-title":"Hum. Gene Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"155ra138","DOI":"10.1126\/scitranslmed.3004414","article-title":"Immunotherapy against HPV16\/18 generates potent TH1 and cytotoxic cellular immune responses","volume":"4","author":"Bagarazzi","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1038\/ncomms6317","article-title":"Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients","volume":"5","author":"Kim","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_82","unstructured":"ClinicalTrials.gov (2021, October 28). Vaccine Therapy with or without Imiquimod in Treating Patients with Grade 3 Cervical Intraepithelial Neoplasia, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00788164."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1089\/hum.2014.024","article-title":"Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine","volume":"25","author":"Rosales","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"ref_84","unstructured":"Inovio Pharmaceutical Inc. (2022, January 21). INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, Its DNAbased HPV Immunotherapy for the Treatment of High-Grade Precancerous Cervical Dysplasia Caused by HPV-16 and\/or HPV-18. Available online: https:\/\/www.prnewswire.com\/news-releases\/inovio-announces-positive-results-from-reveal-1-a-phase-3-pivotal-trial-evaluating-vgx-3100-its-dna-based-hpv-immunotherapy-for-the-treatment-of-high-grade-precancerous-cervical-dysplasia-caused-by-hpv-16-andor-hpv-18-301237793.html."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1158\/1078-0432.CCR-19-1513","article-title":"A Phase II, Prospective, Randomized, Multicenter, Open-Label Study of GX-188E, an HPV DNA Vaccine, in Patients with Cervical Intraepithelial Neoplasia 3","volume":"26","author":"Choi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s00262-004-0501-4","article-title":"Phase I\/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia","volume":"53","author":"Hallez","year":"2004","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e002547","DOI":"10.1136\/jitc-2021-002547","article-title":"HPV-16 E6\/E7 DNA tattoo vaccination using genetically optimized vaccines elicit clinical and immunological responses in patients with usual vulvar intraepithelial neoplasia (uVIN): A phase I\/II clinical trial","volume":"9","author":"Bakker","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00262-020-02720-7","article-title":"A phase 1, single centre, open label, escalating dose study to assess the safety, tolerability and immunogenicity of a therapeutic human papillomavirus (HPV) DNA vaccine (AMV002) for HPV-associated head and neck cancer (HNC)","volume":"70","author":"Chandra","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_89","first-page":"3676","article-title":"Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer","volume":"8","author":"Kaufmann","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13578-017-0171-5","article-title":"Enhancing antitumor immunogenicity of HPV16-E7 DNA vaccine by fusing DNA encoding E7-antigenic peptide to DNA encoding capsid protein L1 of Bovine papillomavirus","volume":"7","author":"Yang","year":"2017","journal-title":"Cell Biosci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1016\/j.vaccine.2017.05.081","article-title":"Characterization of HPV18 E6-specific T cell responses and establishment of HPV18 E6-expressing tumor model","volume":"35","author":"Ma","year":"2017","journal-title":"Vaccine"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"De Oliveira, L.M., Morale, M.G., Chaves, A.A., Cavalher, A.M., Lopes, A.S., Mde, O.D., Schanoski, A.S., de Melo, R.L., Ferreira, L.C., and de Oliveira, M.L. (2015). Design, Immune Responses and Anti-Tumor Potential of an HPV16 E6E7 Multi-Epitope Vaccine. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0138686"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s002620000125","article-title":"A recombinant vaccinia virus containing the papilloma E2 protein promotes tumor regression by stimulating macrophage antibody-dependent cytotoxicity","volume":"49","author":"Rosales","year":"2000","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1002\/(SICI)1097-0142(20000401)88:7<1650::AID-CNCR20>3.0.CO;2-L","article-title":"Human tumor growth is inhibited by a vaccinia virus carrying the E2 gene of bovine papillomavirus","volume":"88","author":"Graham","year":"2000","journal-title":"Cancer"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/sj.cgt.7700937","article-title":"Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine","volume":"13","author":"Contreras","year":"2006","journal-title":"Cancer Gene Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.bpobgyn.2005.02.008","article-title":"Management of cervical premalignant lesions","volume":"19","author":"Lindeque","year":"2005","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1016\/j.vaccine.2008.03.069","article-title":"Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6\/E7 fusion consensus protein in mice and rhesus macaques","volume":"26","author":"Yan","year":"2008","journal-title":"Vaccine"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.vaccine.2008.10.078","article-title":"Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6\/E7 fusion antigen","volume":"27","author":"Yan","year":"2009","journal-title":"Vaccine"},{"key":"ref_99","unstructured":"Sardesai, N. (2012). Cervical cancer immunotherapy: Induction of HPV specific CTLs in human volunteers after VGX-3100 immunization. ECI Digital Archive: Vaccine Technology IV, Engineering Conferences International (ECI)."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2\/3: A randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"key":"ref_101","unstructured":"ClinicalTrials.gov (2021, October 27). REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03721978."},{"key":"ref_102","unstructured":"Inovio Pharmaceutical Inc. (2022, January 21). INOVIO\u2019s VGX-3100 Demonstrates Positive Phase 2 Efficacy in Treatment of Precancerous Anal Dysplasia Caused by HPV-16\/18. Available online: https:\/\/ir.inovio.com\/news-releases\/news-releases-details\/2020\/INOVIOs-VGX-3100-Demonstrates-Positive-Phase-2-Efficacy-In-Treatment-of-Precancerous-Anal-Dysplasia-Caused-by-HPV-1618\/default.aspx."},{"key":"ref_103","unstructured":"Inovio Pharmaceutical Inc. (2022, January 21). INOVIO\u2019s VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Vulvar Dysplasia Caused by HPV-16\/18. Available online: https:\/\/ir.inovio.com\/news-releases\/news-releases-details\/2021\/INOVIOs-VGX-3100-Demonstrates-Positive-Phase-2-Efficacy-In-Treatment-of-Precancerous-Vulvar-Dysplasia-Caused-by-HPV-1618\/default.aspx."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1099\/0022-1317-78-10-2615","article-title":"Identification of a cytotoxic T-lymphocyte epitope in the human papillomavirus type 16 E2 protein","volume":"78","author":"Konya","year":"1997","journal-title":"J. Gen. Virol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.4049\/jimmunol.164.9.4635","article-title":"Increased DNA vaccine delivery and immunogenicity by electroporation in vivo","volume":"164","author":"Widera","year":"2000","journal-title":"J. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0168-1656(00)00308-4","article-title":"Enhancement of DNA vaccine potency by electroporation in vivo","volume":"83","author":"Selby","year":"2000","journal-title":"J. Biotechnol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/j.vaccine.2003.11.073","article-title":"Enhancement of DNA vaccine potency in rhesus macaques by electroporation","volume":"22","author":"Otten","year":"2004","journal-title":"Vaccine"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1128\/JVI.00055-07","article-title":"Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques","volume":"81","author":"Luckay","year":"2007","journal-title":"J. Virol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"7240","DOI":"10.1016\/j.vaccine.2017.11.011","article-title":"In vivo electroporation enhances vaccine-mediated therapeutic control of human papilloma virus-associated tumors by the activation of multifunctional and effector memory CD8+ T cells","volume":"35","author":"Sales","year":"2017","journal-title":"Vaccine"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2217\/bmm-2016-0174","article-title":"Utilizing selection biomarkers in clinical trials: Is this the future of drug development?","volume":"10","author":"Carroll","year":"2016","journal-title":"Biomark. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ygyno.2019.03.250","article-title":"The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up","volume":"153","author":"Harper","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_113","unstructured":"Hillemanns, P., Petry, K., Woelber, L., B\u00f6hmer, G., Stubsrud, E., Skj\u00f8restad, I., Schjetne, K., Fredriksen, A., and Axelsen, M. (April, January 29). Safety, efficacy and immunogenicity of VB10.16, a therapeutic DNA vaccine targeting human papillomavirus (HPV) 16 E6 and E7 proteins for high grade cervical intraepithelial neoplasia (CIN 2\/3): 6-month data from an exploratory open-label phase I\/2a trial. Proceedings of the American Association for Cancer Research (AACR) Annual Meeting, Atlanta, GA, USA."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"S645","DOI":"10.1016\/j.annonc.2020.08.1020","article-title":"A multi-centre, open-label phase II trial of the combination of VB10.16 and atezolizumab in patients with advanced or recurrent, non-resectable HPV16 positive cervical cancer","volume":"31","author":"Hillemanns","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/CJI.0000000000000156","article-title":"DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection","volume":"40","author":"Chandra","year":"2017","journal-title":"J. Immunother."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Lorenz, F.K., Wilde, S., Voigt, K., Kieback, E., Mosetter, B., Schendel, D.J., and Uckert, W. (2015). Codon optimization of the human papillomavirus E7 oncogene induces a CD8+ T cell response to a cryptic epitope not harbored by wild-type E7. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0121633"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/intimm\/dxw030","article-title":"Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation","volume":"28","author":"Yaguchi","year":"2016","journal-title":"Int. Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1021\/acsnano.7b07874","article-title":"Macrophage-Specific in vivo Gene Editing Using Cationic Lipid-Assisted Polymeric Nanoparticles","volume":"12","author":"Luo","year":"2018","journal-title":"ACS Nano"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014A new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"Pulendran","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coi.2017.06.005","article-title":"Old and new adjuvants","volume":"47","author":"McKee","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41577-018-0044-0","article-title":"CD4+ T cell help in cancer immunology and immunotherapy","volume":"18","author":"Borst","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1084\/jem.20030324","article-title":"Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein","volume":"198","author":"Fujii","year":"2003","journal-title":"J. Exp. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s12307-011-0066-7","article-title":"Immunosuppressive tumor microenvironment in cervical cancer patients","volume":"4","author":"Piersma","year":"2011","journal-title":"Cancer Microenviron."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40425-018-0485-9","article-title":"Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy","volume":"7","author":"Hanoteau","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"B21","DOI":"10.1016\/j.vaccine.2014.12.082","article-title":"Beyond adjuvants: Immunomodulation strategies to enhance T cell immunity","volume":"33","author":"Kamphorst","year":"2015","journal-title":"Vaccine"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc.2016.16","article-title":"Vaccines for established cancer: Overcoming the challenges posed by immune evasion","volume":"16","author":"Arens","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ctrv.2019.07.001","article-title":"The promise of combining cancer vaccine and checkpoint blockade for treating HPV-related cancer","volume":"78","author":"Shibata","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00705-016-3091-5","article-title":"Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine","volume":"162","author":"Moeini","year":"2017","journal-title":"Arch. Virol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","article-title":"Tumor-infiltrating lymphocytes in the immunotherapy era","volume":"18","author":"Paijens","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1016\/j.molonc.2015.10.018","article-title":"Tumor-infiltrating lymphocytes for the treatment of metastatic cancer","volume":"9","author":"Foppen","year":"2015","journal-title":"Mol. Oncol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/14737140.2018.1445527","article-title":"Current research into novel therapeutic vaccines against cervical cancer","volume":"18","author":"Cordeiro","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1200\/JCO.1990.8.11.1789","article-title":"Prognostic value of c-myc proto-oncogene overexpression in early invasive carcinoma of the cervix","volume":"8","author":"Bourhis","year":"1990","journal-title":"J. Clin. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1158\/1078-0432.CCR-06-1568","article-title":"High human papillomavirus oncogene mRNA expression and not viral DNA load is associated with poor prognosis in cervical cancer patients","volume":"13","author":"Jordanova","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/bjc.2013.639","article-title":"Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer","volume":"110","author":"Ward","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1916-0216-42-23","article-title":"Cyclin D1 overexpression is associated with poor prognosis in oropharyngeal cancer","volume":"42","author":"Lin","year":"2013","journal-title":"J. Otolaryngol. Head Neck Surg."},{"key":"ref_138","first-page":"3187","article-title":"High MALAT1 expression predicts a poor prognosis of cervical cancer and promotes cancer cell growth and invasion","volume":"19","author":"Yang","year":"2015","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/d41573-020-00151-8","article-title":"Evolution of the COVID-19 vaccine development landscape","volume":"19","author":"Le","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Setting","volume":"385","author":"Barda","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jconrel.2021.03.043","article-title":"The dawn of mRNA vaccines: The COVID-19 case","volume":"333","author":"Verbeke","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA COVID-19 Vaccine in a Nationwide Mass Vaccination Setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jama.2021.15072","article-title":"Surveillance for Adverse Events After COVID-19 mRNA Vaccination","volume":"326","author":"Klein","year":"2021","journal-title":"JAMA"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.15585\/mmwr.mm7032e4","article-title":"Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices\u2013United States, July 2021","volume":"70","author":"Rosenblum","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_146","unstructured":"Hopkins, J. (2022, January 21). FDA Authorizes Pfizer Vaccine for Young Children. Wall Str. J., Available online: https:\/\/www.msn.com\/en-us\/health\/medical\/fda-authorizes-pfizer-vaccine-for-young-children\/ar-AAQ6F2u?li=BBnb7Kz."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"101142","DOI":"10.1016\/j.nantod.2021.101142","article-title":"Role of nanotechnology behind the success of mRNA vaccines for COVID-19","volume":"38","author":"Khurana","year":"2021","journal-title":"Nano Today"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.actbio.2021.06.023","article-title":"From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases","volume":"131","author":"Pilkington","year":"2021","journal-title":"Acta Biomater."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/2\/239\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:07:42Z","timestamp":1760134062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/2\/239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,25]]},"references-count":148,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["v14020239"],"URL":"https:\/\/doi.org\/10.3390\/v14020239","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,25]]}}}